Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.69 |
| ▸ | TP53 | P04637 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9400583 | 0.86 | MEN1 (0.73) | MEN1KMT2ATP53MAPTCYP1A2 | |
| Oxalic Acid SCHEMBL9400518 | 0.84 | MEN1 (0.69) | MEN1KMT2ATP53MAPTCYP1A2 | |
| SCHEMBL29729330 | 0.82 | MAPT (1.00) | MEN1KMT2ATP53MAPTCYP1A2 | |
| SCHEMBL29391435 | 0.82 | MAPT (1.00) | MEN1KMT2ATP53MAPTCYP1A2 | |
| SCHEMBL173735 | 0.82 | MAPT (1.00) | MEN1KMT2ATP53MAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL31077673 | 0.81 | HTR2C (1.00) | MEN1KMT2ATP53MAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL2116886 | 0.81 | HTR2C (1.00) | MEN1KMT2ATP53MAPTCYP1A2 | |
| SCHEMBL9400617 | 0.75 | MEN1 (0.82) | MEN1KMT2ATP53MAPTCYP1A2 | |
| SCHEMBL1743495 | 0.74 | IMPDH2 (0.69) | MEN1KMT2ATP53MAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL9400545 | 0.74 | HTR2C (0.82) | MEN1KMT2ATP53MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240091387-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| US-11802138-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-31 | — | — | US | disclosed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210363186-A1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
| US-20210087229-A1 | Optimized Peptides for Targeting Human Nerves and Their Use in Image Guided Surgery, Diagnostics and Therapeutic Delivery | UNIV CALIFORNIA (US) | 2021-03-25 | — | — | US | disclosed |
| US-10596259-B2 | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-24 | — | — | US | disclosed |
| US-10385380-B2 | Personalized protease assay to measure protease activity in neoplasms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | disclosed |
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180140703-A1 | TUMOR RADIOSENSITIZATION WITH ANTIBODY CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-24 | — | — | US | disclosed |
| US-20170080088-A1 | TUMOR RADIOSENSITIZATION WITH MONOMETHYL AURISTATIN E (MMAE) AND DERIVATIVES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-20160160263-A1 | PERSONALIZED PROTEASE ASSAY TO MEASURE PROTEASE ACTIVITY IN NEOPLASMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-09 | — | — | US | disclosed |
| US-20150359902-A1 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARLY RELEASABLE PRODRUG | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | DNPEP, FOLH1, CTSL | MEN1 523/4885KMT2A 3601/4885TP53 368/4885 |
| US-10596259-B2 | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof | AURKA, AURKB, MMAB | MEN1 111/4885KMT2A 1390/4885TP53 232/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | MEN1 1105/4885KMT2A 4260/4885TP53 1522/4885 |
| US-20170080088-A1 | TUMOR RADIOSENSITIZATION WITH MONOMETHYL AURISTATIN E (MMAE) AND DERIVATIVES THEREOF | AURKA, AURKB, MMAB | MEN1 111/4885KMT2A 1390/4885TP53 232/4885 |
| US-20150359902-A1 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARLY RELEASABLE PRODRUG | DNPEP, FOLH1, CTSL | MEN1 523/4885KMT2A 3601/4885TP53 368/4885 |
| US-20180140703-A1 | TUMOR RADIOSENSITIZATION WITH ANTIBODY CONJUGATES | MMAB, AURKB, AURKC | MEN1 100/4885KMT2A 1895/4885TP53 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.